PMV Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The company is a clinical-stage precision oncology business developing small-molecule therapies targeting mutant p53. It has no approved products and has not generated revenue.
Financial performance and position
- Revenue: None. The filing says product revenue is not expected in the foreseeable future.
- Operating expenses: $21.5 million, up $2.9 million from $18.6 million in Q1 2022. Research and development was $15.1 million, up $3.2 million; general and administrative expense was $6.4 million, down $0.4 million.
- Loss: Net loss was $19.1 million, compared with $18.4 million in Q1 2022. Basic and diluted loss per share was $0.42 versus $0.41. No operating margin is meaningful because the company has no revenue.
- Interest income: $2.3 million, up $2.1 million year over year, primarily reflecting higher interest rates on cash and investments.
- Cash flow: Cash used in operations was $15.0 million, compared with $18.0 million in Q1 2022. Investing activities provided $49.6 million, largely from $73.3 million of marketable securities maturities, partly offset by purchases. Cash and cash equivalents increased $34.6 million during the quarter; this increase does not represent positive operating cash flow.
- Liquidity: Cash, cash equivalents and marketable securities totaled $229.4 million at March 31, 2023, down $14.1 million from December 31, 2022. Working capital was $222.7 million. Management says available funds should support operations at least through 2024, subject to assumptions.
- Debt and commitments: The filing reports no borrowings; operating lease liabilities totaled $13.5 million. The Princeton office and laboratory lease runs through 2032, with future minimum lease payments of $17.6 million before imputed interest.
Material changes versus Q1 2022
- R&D spending increased mainly because of development costs for lead candidate PC14586 in its Phase 1/2 trial, as well as personnel and stock-based compensation. Research expense declined.
- G&A expense declined, mainly due to lower audit and insurance costs, partly offset by costs for the new Princeton facility.
- Higher interest income partly offset increased operating expenses, but net loss still increased by $0.7 million.
Outlook, risks and other notable items
- Management expects substantial additional losses and higher R&D investment in the remainder of 2023 and in 2024. It cannot reliably estimate development timelines, completion costs, or when, if ever, the company will generate product revenue or become profitable.
- PC14586 is in a Phase 1/2 clinical trial and received FDA Fast Track Designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation. The filing describes prior initial Phase 1 data presentation in June 2022; it provides no new trial results in this quarter’s financial discussion.
- The company expects to fund operations through its existing resources and may need additional equity, debt, collaboration or other financing. It had not sold securities under its shelf registration or at-the-market program as of March 31, 2023. Additional equity could dilute shareholders; financing may not be available on acceptable terms.
- Key risks include clinical and regulatory uncertainty, competition, reliance on third-party research and manufacturing providers, and the possibility that capital is consumed faster than expected. The filing also discusses risks to access to uninsured bank deposits amid financial-sector disruption; the company says it had no deposits at the specifically affected banks mentioned.
- No material litigation was reported. Management concluded disclosure controls were effective at the reasonable-assurance level as of March 31, 2023.
Facts investors should verify
- Current PC14586 trial progress, safety and efficacy data, and expected timing of further disclosures.
- Whether the stated cash runway through 2024 remains supportable as clinical spending and other costs evolve.
- Quarterly operating cash use and the composition, maturity and liquidity of cash and marketable securities.
- Potential financing needs, use of the shelf or ATM program, and resulting dilution or debt obligations.